title: [Effect of xunxi no.1 intervention and radiotherapy on Ia-IIb stage cervical cancer with high-risk human papilloma virus infection].
abstract: OBJECTIVE
  To explore the clinical value of Chinese medical intervention and treatment of high-risk human papilloma virus (HR-HPV) infection in patients of cervical cancer (CC) during radiotherapy (RT).
  
  
  METHODS
  Eighty CC patients of the Ia-IIb stage receiving primary RT were assigned to two groups. RT and local intervention by Xunxi No. 1 was given to patients in the test group for 20 days, while patients in the control group were treated with RT alone. Expression of high-risk HPV (HR-HPV, HPV16/18 infection) was detected by in-situ hybridization (ISH) before and after treatment. The 5-year disease free survival rate and pelvic lymph node metastasis rate (with the lymph node diameter >0.9 cm shown by CT) in patients were observed.
  
  
  RESULTS
  After treatment, the HR-HPV positive rate was lowered from 67.5% (27/40) to 37.5% (15/40) in the test group (P<0.05), while it was lowered from 72.5% (29/40) to 65.0% (26/40) in the control group (P>0.05). By follow-ups, the 3-year disease free survival rate in the test group was better than that in the control group (33/40 vs 27/40), showing insignificant difference between the two groups (P>0.05). Significant difference was shown in the 5-year disease free survival rate and the pelvic lymph node metastasis rate (65.0% vs 42.5%, 7.5% vs 25.0%) between the two groups (both P<0.05).
  
  
  CONCLUSIONS
  In early RT of CC, combined application of Xunxi No. 1 could obviously lower the HPV positive rate. The 5-year disease free survival rate was superior to that in the control group, with lower pelvic lymph node metastasis rate. Xunxi No. 1 had better clinical value in clinical application.
authors.affiliation: First Clinical College, Nanjing University of Traditional Chinese Medicine,Nanjing 210029.
authors.forename: Pei-ying
authors.initials: PY
authors.lastname: Zhang
authors.forename: Ling
authors.initials: L
authors.lastname: Liu
authors.forename: Xu-bo
authors.initials: XB
authors.lastname: Wang
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000000981:diagnostic imaging / Q000628:therapy*; D008517:Phytotherapy; D011859:Radiography; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy* / Q000821:virology; D055815:Young Adult
chemical_list: D004365:Drugs, Chinese Herbal